CD8A and colorectal carcinoma: Monocytes/Macrophages S01 and CD8 T cell S01 were the most significantly associated with therapeutic benefit of CRC (Fig. 7a, p-values = 0.0011 and 0.0015), indicating that fluorouracil-based ACT might be most suitable for CRC patients within two cellular states.